Drug profile · INN
ixazomib
NINLARO
ixazomib (NINLARO) is a 26s proteasome inhibitor. Associated with Takeda.
EMA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01XG03
Patents linked 0
Pipeline programs 34
News articles 0
Drug details — ixazomib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 34
- Data quality
- 0.89
Quick answer
ixazomib (NINLARO) is a 26s proteasome inhibitor. Associated with Takeda.
Key facts
INN ixazomib
Brand NINLARO
Mechanism 26S proteasome inhibitor
Target 26S proteasome
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XG03
Originator Takeda
Mechanism of action
26S proteasome inhibitor
Primary target: 26S proteasome
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ixazomib?
ixazomib (NINLARO) is a 26s proteasome inhibitor. Associated with Takeda.
What is the brand name for ixazomib?
NINLARO is a marketed brand name for ixazomib. Check FDA Drugs@FDA for the current US label holder and prescribing information.